Individualized therapy in Multiple Myeloma

Presented by: Shaji Kumar, M.D., Mark and Judy. Mullins Professor of Hematological Malignancies. Chair, Myeloma and Amyloidosis Group, Mayo Clinic, Rochester, MN.

Covered by: Abdul Moiz Khan, M.D, Chief Fellow of Hematology and Oncology at Karmanos Cancer Institute, Detroit, MI.

 

Shaji Kumar, M.D., Mark and Judy. Mullins Professor of Hematological Malignancies, Mayo Clinic, Rochester, MN

Dr. Shaji Kumar, a key opinion leader in multiple myeloma (MM), discussed the importance of understanding the drivers of heterogeneity to help individualize treatment for MM patients. These differences are the result of an interplay of multiple host and disease factors. With our improved understanding of disease biology and behavior, MM should be considered a group of disorders with a common morphology, yet distinct genetic subgroups. This may enable personalization of therapy by using multidrug combinations or specific class of drugs, varying the duration of therapy, or targeting a particular level of response.

 

Venetoclax in t(11;14) MM serves as a prototypical example of precision medicine in MM. Dr. Kumar reviewed our evolving knowledge of MM genome and how basket, umbrella or platform trial designs may pave way for bringing drugs from bench to bedside. He cited the example of Myeloma-Developing Regimens Using Genomics (MyDRUG) (NCT02884102) trial which aims at treating patients with drugs targeted to affect specific mutated genes. Looking ahead, novel targeted therapies carry a promise to achieve the goal of individualized medicine with improved outcomes in MM.

 

  1. Shaji Kumar, et al.Blood 2017; 130 (22): 2401–2409.
  2. https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2019-00698&r=1
Staff Writer - The Cancer News

Recent Posts

ADRIATIC: durvalumab (D) as consolidation treatment (tx) for patients (pts) with limited-stage small-cell lung cancer (LS-SCLC)

By: Tiantian Zhang1, Yiqun Han2, Lei Deng3 1. Department of Internal Medicine, University of Central…

6 months ago

ASCO24 LAURA Trial Summary

By: Zhiting Tang1, Lei Deng21. Unity Hospital, Rochester Regional Health, Rochester, NY2. University of Washington/Fred…

6 months ago

FDA Approves Tovorafenib for Pediatric Low-Grade Glioma With BRAF Mutation

By: Dr. Anish Shah Bronx-Lebanon Hospital; Bronx, NY On April 23, 2024, the U.S. Food and Drug…

7 months ago

FDA Approves Tisotumab Vedotin for Recurrent or Metastatic Cervical Cancer

By: Dr. Anish Shah Bronx-Lebanon Hospital; Bronx, NY On April 29, 2024, the U.S. Food and Drug…

7 months ago

FDA Approves Lutetium Lu 177 Dotatate for SSTR-Positive Gastroenteropancreatic Neuroendocrine Tumors

By: Dr. Anish Shah Bronx-Lebanon Hospital; Bronx, NY On April 23, 2024, the U.S. Food and Drug…

7 months ago

FDA Approves Alectinib for Adjuvant Treatment in Non-Small Cell Lung Cancer

By: Dr. Anish Shah Bronx-Lebanon Hospital; Bronx, NY On April 18, 2024, the U.S. Food and Drug…

7 months ago